Wilson Disease Association Releases Voice of the Patient Report Highlighting Needs in Diagnosis, Treatment, and Daily Life

Report captures perspectives shared by patients, caregivers, and families during Externally-Led Patient-Focused Drug Development meeting

August 14, 2026 — The Wilson Disease Association has released the Wilson Disease Voice of the Patient report, a comprehensive account of the experiences, needs, and priorities of people living with Wilson disease, their families, and caregivers.

The report summarizes input shared during the Wilson Disease Externally-Led Patient-Focused Drug Development meeting held virtually on Jan. 29, 2026. It provides regulators, medical product developers, researchers, and clinicians with a resource to help inform regulatory decision-making, research priorities, clinical care, and the development of new treatments.

More than 350 people attended the meeting livestream, including 40 FDA staff members. Patients and caregivers shared their perspectives through panel discussions, recorded presentations, telephone comments, online polling, and written submissions.

“This report places the voices of patients, caregivers, and families at the center of the conversation about Wilson disease,” said Rhonda Rowland, President of the Wilson Disease Association. “Their experiences demonstrate the urgent need for earlier diagnosis, more effective and manageable treatments, and greater support throughout the lifelong Wilson disease journey. We are deeply grateful to everyone who shared their story and helped make this report possible.”

The report highlights recurring challenges across the Wilson disease community, including delayed or incorrect diagnosis; hepatic, neurologic, and psychiatric symptoms; and the effects of the disease on work, school, relationships, and independent living. Participants also described the burden of treatment regimens that can require multiple daily doses, fasting, careful meal timing, special storage, and frequent laboratory monitoring, as well as concerns about side effects, effectiveness, access, and affordability.

Among the community’s highest priorities are treatments that can slow or stop disease progression, improve or reverse neurologic symptoms, and be administered more easily. Participants also identified needs for expanded mental health support, additional research involving children and pregnant patients, newborn screening, and better screening for Wilson disease among psychiatric patients.

The report, accompanying polling results, and additional patient and caregiver comments are available at:

wilsondisease.org/get-involved/events/voice-of-the-patient-report/

About the Wilson Disease Association

The Wilson Disease Association is a 501(c)(3) nonprofit patient advocacy organization that provides support and hope to people affected by Wilson disease worldwide so they may achieve the best possible quality of life. To learn more, visit wilsondisease.org.

Media Contact:
Rhonda Rowland
President
Wilson Disease Association
866-961-0533
rhonda.rowland@wilsonsdisease.org